The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

Purpose:

This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation

Criteria:

Inclusion Criteria: - Between 18 and 65 years of age at Screening - Diagnosis of Major Depressive Disorder (MDD) - Significant level of suicidal thoughts with active ideation and without immediate intent - Failure to respond to 2 medications in the current episode Exclusion Criteria: - Current or past history of schizophrenia, psychotic disorder, bipolar disorder, borderline personality disorder, etc. - Current alcohol or substance use disorder

NCT ID:

NCT05220410

Primary Contact:

Principal Investigator
Scott Aaronson, MD
Sheppard Pratt Health System

Sam Rudow
Phone: (410) 938-3126
Email: srudow@sheppardpratt.org

Backup Contact:

Email: audrey.shoultz@sheppardpratt.org
Audrey Shoultz
Phone: (410) 938-5263

Location Contact:

Baltimore, Maryland 21204
United States

Sam Rudow
Phone: 410-938-3126
Email: srudow@sheppardpratt.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: June 28, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.